June 11, 2026

Fat hack protects against cell death

Fat hack protects against cell death

In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis. In the long term, these findings could provide new avenues for cancer therapies and the treatment of age-related diseases.

Senescence occurs when cells respond to stress or harmful changes and permanently cease their growth. This process is considered a protective mechanism against cancer. Cells that, for example, carry an oncogene permanently activated by mutations are effectively “frozen” before they can proliferate uncontrollably—a biological emergency program. However, problems arise when senescent cells accumulate in tissue, where they promote chronic inflammation and thus facilitate tumor development. Scientists are therefore searching for ways to eliminate senescent cells before they can cause harm.

The research team led by Almut Schulze investigated, using connective tissue cells, how the metabolism of senescent cells changes when induced by the mutated BRAFV600E oncogene. The BRAFV600E mutation is common, for example, in melanomas. The experiments revealed that the cells produce large amounts of triglycerides—i.e., storage fats—and store them in small lipid droplets.

This redistribution of fats has far-reaching consequences: particularly sensitive polyunsaturated fatty acids are removed from cell membranes and incorporated into stored fats instead. This makes the cell membranes more resistant to oxidative damage. The cells thus protect themselves from ferroptosis, a form of programmed cell death triggered by lipid oxidation.

The researchers identified the metabolic enzyme DGAT1 as a central key factor in this protective mechanism. When they blocked it, the sensitive fatty acids returned in greater quantities to the cell membranes—and the senescent cells lost their resistance to ferroptosis.

Furthermore, the altered lipid metabolism also appears to influence the cells’ inflammatory responses. Senescent cells produced increased levels of so-called oxylipins—pro-inflammatory lipid messengers. The combination of DGAT1 inhibition and the blockade of oxylipin production fully restored the cells’ sensitivity to ferroptosis.

“The results provide us with new insights into the biology of senescent cells,” says study leader Almut Schulze. “They show how closely lipid metabolism, inflammatory processes, and cell survival are linked.” The researchers view this work as a foundation for developing new therapeutic strategies in the long term that can specifically eliminate senescent cells. This would not only be an option for treating cancer but potentially also for age-related diseases.

Publication:

Markus S. Hess, Kamal M. Al-Shami, Carolina Dehesa Caballero, Julie Haenlin, Adriano B. Chaves-Filho, Lisa Schlicker, Philipp Poeller, Felix C. E. Vogel, Ioanna Koltsaki, Deniz Gedik, Marta Campos Alonso, Susanne Walz, Carsten P. Ade, Martin Eilers, Beate K. Straub, Jochen S. Utikal, Svenja Meierjohann, Mathias T. Rosenfeldt, Marteinn T. Snaebjornsson, and Almut Schulze: Fatty acid channelling into triglycerides and oxylipins drives ferroptosis resistance during oncogenic BRAF-induced senescence.

Dell Death & Differentiation 2026, https://doi.org/10.1038/s41418-026-01766-x

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp